Dual skin testing for latent tuberculosis infection: A decision analysis

American Journal of Preventive Medicine

Volumn 24, Issue 3, 2003, Pages 254-259

  Hersh, Adam L ^a,b   Tosteson, Anna N ^b,c   Von Reyn, C Fordham ^c  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DARTMOUTH MEDICAL SCHOOL   (United States)

^c DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; HUMAN; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MEDICAL DECISION MAKING; SENSITIVITY AND SPECIFICITY; TUBERCULIN TEST;

EID: 0037378150     PISSN: 07493797     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0749-3797(02)00584-6     Document Type: Article

References (27)

1. Targeted tuberculin testing and treatment of latent tuberculosis infection. MMWR Morb Mort Wkly Rep. 49:2000;1-51.
2. Rose D.N., Schecter C.B., Adler J.J. Interpretation of the tuberculin skin test. J Gen Intern Med. 10:1995;635-642.
3. Diagnostic standards and classification of tuberculosis in adults and children. Am J Respir Crit Care Med. 161:2000;1376-1395.
4. von Reyn C.F., Horsburgh C.R., Olivier K.N., et al. Skin test reactions to Mycobacterium tuberculosis purified protein derivative and Mycobacterium avium sensitin among health care workers and medical students in the United States. Int J Tuberc Lung Dis. 12:2001;1122-1128.
5. Marcus A.M., Rose D.N., Sacks H.S., Schechter C.B. BCG vaccination to prevent tuberculosis in health care workers a decision analysis. Prev Med. 26:1997;201-207.
6. Smith D.T. Diagnostic and prognostic significance of the quantitative tuberculin tests the influence of subclinical infection with atypical mycobacteria. Ann Intern Med. 67:1967;919-946.
7. Edwards L.B., Acquaviva F.A., Livesay V.T. Identification of tuberculosis infected Dual tests and density of reaction. Am Rev Resp Dis. 108:1973;1334-1339.
8. Palmer C.E., Edwards L.B. Identifying the tuberculous infected the dual-test technique. JAMA. 205:1968;117-119.
9. Prince D.S., Peterson D.D., Steiner R.M., et al. Infection with Mycobacterium avium complex in patients without predisposing conditions. N Engl J Med. 321:1989;863-868.
10. Horsburgh C.R. Jr. Mycobacterium avium complex infection in the acquired immunodeficiency syndrome. N Engl J Med. 324:1991;1332-1338.
11. Kennedy T.P., Weber D.J. Nontuberculous mycobacteria an underappreciated cause of geriatric lung disease. Am J Respir Crit Care Med. 149:1994;1654-1658.
12. Cox J.N., Brenner E.R., Bryan C.S. Changing patterns of mycobacterial disease at a teaching community hospital. Infect Control Hosp Epidemiol. 15:1994;513-515.
13. Stuart R.L., Wilson J., Grayson M.L. Isoniazid toxicity in health care workers. Clin Infec Dis. 28:1999;895-897.
14. von Reyn C.F., Barber T.W., Arbeit R.D., et al. Evidence of previous infection with Mycobacterium avium-Mycobacterium intracellularae complex among healthy subjects an international study of dominant mycobacterial skin test reactions. J Infect Dis. 168:1993;1553-1558.
15. Bruins J., Gribnau J.H., Bwire R. Investigation into typical and atypical tuberculin sensitivity in the Royal Netherlands Army, resulting in a more rational indication for isoniazid prophylaxis. Tuberc Lung Dis. 76:1995;540-544.
16. von Reyn C.F., Green P.A., McCormick D., et al. Dual skin testing with Mycobacterium avium sensitin and purified protein derivative an open study of patients with M. avium complex infection or tuberculosis. Clin Infect Dis. 19:1994;15-20.
17. von Reyn C.F., Williams D.E., Horsburgh C.R. Jr, et al. Dual skin testing with Mycobacterium avium sensitin and purified protein derivative to discriminate pulmonary disease due to M. avium complex from pulmonary disease due to Mycobacterium tuberculosis. J Infect Dis. 177:1998;730-736.
18. Iseman M. A 52-year-old man with a positive PPD. JAMA. 286:2001;2015-2022.
19. Cross ER, Hyams KC. Tuberculin skin testing in US Navy and Marine Corps personnel and recruits 1980-86. Am J Public Health 1990;80435-8.
20. Trump D.H., Hyams K.C., Cross E.R., Sruewing J.P. Tuberculosis infection among young adults entering the US Navy in 1990. Arch Intern Med. 153:1993;211-216.
21. Lee E., Holzman R.S. Evolution and current use of the tuberculin test. Clin Infect Dis. 34:2002;365-370.
22. Jasmer R.M., Snyder D.C., Chin D.P., et al. Twelve months of isoniazid compared with four months of isoniazid and rifampin for persons with radiographic evidence of previous tuberculosis. Am J Respir Crit Care Med. 162:2000;1648-1652.
23. Snider D.C., Chin D.P. Cost-effectiveness analysis of directly observed therapy for patients with tuberculosis at low risk for treatment default. Am J Respir Crit Care Med. 160:1999;582-586.
24. Mazurek G.H., Lobue P.A., Daley C.L., et al. Comparison of a whole-blood interferon λ assay with tuberculin skin testing for detecting latent Mycobacterium tuberculosis infection. JAMA. 286:2001;1740-1747.
25. Hersh A., von Reyn C.F. Interferon assay compared to tuberculin skin testing for latent tuberculosis detection. JAMA. 287:2002;450-451.
26. Herzmann C. Interferon assay compared to tuberculin skin testing for latent tuberculosis detection. JAMA. 287:2002;451-452.
27. Nolan C.M., Goldberg S.V., Buskin S.E. Hepatotoxicity associated with isoniazid preventive therapy. JAMA. 281:1999;1014-1018.